Palmar plantar erythrodysesthesia natural history, complications, and prognosis
Palmar plantar erythrodysesthesia Microchapters |
Differentiating Palmar plantar erythrodysesthesia from other Diseases |
---|
Diagnosis |
Treatment |
Palmar plantar erythrodysesthesia natural history, complications, and prognosis On the Web |
American Roentgen Ray Society Images of Palmar plantar erythrodysesthesia natural history, complications, and prognosis |
FDA on Palmar plantar erythrodysesthesia natural history, complications, and prognosis |
CDC on Palmar plantar erythrodysesthesia natural history, complications, and prognosis |
Palmar plantar erythrodysesthesia natural history, complications, and prognosis in the news |
Blogs on Palmar plantar erythrodysesthesia natural history, complications, and prognosis |
Directions to Hospitals Treating Palmar plantar erythrodysesthesia |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Zain Fatiwala, M.D.
Overview
Natural History
Initially, the patient of Palmar Plantar Erythrosysesthesia experiences a sensation of numbness/tingling in the palms and soles. This progresses into a painful, tingling, symmetric, well-demarcated swelling with an erythematous plaques. It is followed by a phase of desquamation upon resolution.[1]
One of the complications associated with PPE is loss of fingerprints. It is documented in a patient who was treated with capecitabine and detained at an airport while travelling because of lack of finger prints.[2]
Prognosis
PPE variably recurs with resumption of chemotherapy. Long-term chemotherapy may also result in reversible palmoplantar keratoderma. Symptoms resolve 1-2 weeks after cessation of chemotherapy (Apisarnthanarax and Duvic 2003).
References
- ↑ "Acral Erythema - Holland-Frei Cancer Medicine - NCBI Bookshelf".
- ↑ Wong M, Choo SP, Tan EH (2009). "Travel warning with capecitabine". Ann Oncol. 20 (7): 1281. doi:10.1093/annonc/mdp278. PMID 19470576.